New Investment Opportunity: Magdent
Accelerating bone growth for dental implants
- CE-approved, proprietary, patent-protected adaptation of proven orthopedic technology accelerates critical bone development 3X faster for dental implants, increases bone density, significantly reduces failure rate, improves outcomes
- First-mover advantage, highly differentiated product, no similar device on market; $1.6B global market for dental implants, 12M dental implants used annually in US, Europe
- Standard procedure, similar to the use of similar healing cap, fits with most implants, only real solution for high-risk patients with diabetes, smoking, osteoporosis and other risk factors
- Projecting initial revenue of $550K in 2023, $1.6M 2024, $5.6M 2025
- Board Chairman Prof. Shlomo Barak is serial entrepreneur, Founder of Polypid (NASDAQ: PYPD) $212M IPO; Founder and CEO of Maccabi Dent
- $4M Series C led by Catapult Education, US continuing dental education platform with 100K+ members
BOOK A CALL
with your Investor Relations representative
Dear Josb,
More than 17M dental implants are used each year around the world but millions of them fail, take months to heal, or cause inflammation.
Magdent's novel technology utilizes orthopedically adopted electromagnetic field treatment to stimulate, accelerate, and improve bone formation and quality for more successful dental implant procedures and in a shorter healing time.
OurCrowd is investing in Magdent. The details in this email are based on information received from, and verified solely by, the company.
The Problem
Of the 17M dental implant procedures conducted annually around the world, millions fail. Some 20% of patients are at high risk of failure because they are heavy smokers or suffer from osteoporosis or diabetes. Inflammation, which occurs in more than 40% of cases, can also lead to failure. Even in successful cases, the healing period is 3-6 months, or up to 9 months if a bone graft is required.
The Solution
Magdent improves dental implant procedures using a proprietary pulsed electromagnetic device that stimulates bone formation and bone quality in less time and significantly reduces risk failure. For the first time, Magdent enables dentists to actively shorten and improve the bone-to-implant connection and osseointegration process in dental implant procedures.
Magdent took pulse electromagnetic fields, a clinically proven treatment method commonly used in orthopedics, and developed a Miniaturized Electromagnetic Device (MED), which is similar to simple healing abutments and small enough to fit screwed on top of a dental implant for the first time. Once inserted, it utilizes pulsed electromagnetic fields to stimulate bone formation and bone quality. The Magdent-MED has been clinically proven to reduce the healing process from 6 months to 2 months and increase bone to implant contact by 48%. The MED also has proven success in bone formation even when inflammation is present.
Trials show that the MED increases bone volume density by 62% compared to standard procedures, making it the treatment of choice for patients in high-risk groups with poor bone quality.
The Traction
The Magdent-MED technology is based on a decade of research and trials. The device is CE approved and protected by 17 approved and pending patents. An FDA application is in process. Its advantages have been confirmed and published in Nature: Scientific Reports, the Journal of Craniofacial Surgery, and numerous scientific papers in other leading journals.
Initial commercial sales began in Israel during 2020 and the EU in 2022, with projected revenue of $550K in 2023. The company forecasts revenue of $1.6M in 2024 and $5.6M in 2025.
The Magdent-MED is available in multiple models to fit different brands and can cover 85% of the market.
The Market
The global market of 17M dental implants each year is valued at $2.2B annually. Some 70% of implants are conducted in the US and EU, with an annual value of $1.57B.
The Company
Magdent enjoys first-mover advantage in a large market where there is no other directly competing device or technology.
Magdent was founded in 2011 by Chairman of the Board, Prof. Shlomo Barak, a serial entrepreneur who founded Polypid (NASDAQ: PYPD) which was led to a $212M IPO. Prof. Barak is also the Founder and CEO of Maccabi Dent, a leading Israeli dental provider. He is an internationally recognized oral and maxillofacial surgeon who has published over 45 articles on oral surgery and dentistry.
Moshe Neuman, DMD, Founder & Technology Director, is a highly experienced periodontist who founded Magdent to address the challenges he faced using current implant devices and technologies. He is a diplomate of the American Board of Periodontology and has an M.Sc. in bone biology.
Benny Barak, CEO, has 12+ years of international business experience, including IPOs, M&A transactions, strategic consulting and fundraising around the world.
Elad Yakobson, Chief Operations Officer, has 15+ years of managerial experience, introducing large-scale systems into start-up companies and specializing in business development, R&D, production and operations in the medical devices field.
Magdent has raised $4.6M in previous seed funding, including two grants from the Israel Innovation Authority.
The Round
OurCrowd has a $1.5M allocation in this up to $4M Series C round led by Catapult Education, a US continuing dental education platform that intends to market Magdent's technology to its 100K+ members nationwide. Proceeds will be used to complete the FDA application and expand marketing in the US and Europe.
Meet the CEO
We're hosting a webinar/conference call on Wednesday, December 14th, at 8PM Israel / 1PM New York / 10AM San Francisco for investors to meet CEO Benny Barak and learn more about Magdent.
Can't make the webinar? Register and we will send you a recording of the call.
The Magdent Solution
Magdent's Miniaturized Electromagnetic Device (MED), is small enough to fit most dental implants. The MED is shaped like a simple healing abutment and is easily screwed into the implant. Similar to current medical protocols, it is removed at the end of the treatment period following standard healing abutment placement protocols.
MED is made of titanium. Its hollow structure contains a battery, an electronic device and a coil that fits inside its healing abutment structure, the same way as current simple healing abutments.
The MED's technology actively stimulates and accelerates osteogenesis (bone formation), improving bone quality by 62% and accelerating osseointegration (bone-to-implant connection) by 300%, shortening the healing period by 2/3 after implant placement and enabling the loading of the implant (crown placement) within 1/3 of the usual time.
MED is suitable for patients who may otherwise not be considered good candidates for implants, such as those with poor bone quality and autoimmune diseases (e.g., diabetes, osteoporosis, etc.), as well as heavy smokers.
Advantages of the MED device:
- A treatment for peri-implantitis (inflammation), the #1 cause of pain in the industry
- 300% Acceleration of the healing process
- 48% Increase in bone to implant (BIC)
- Improves bone quality by 62% (increase in trabecular bone volume density) – the best solution for patients with poor bone quality
- Less damage to bone
- Increases the success rates of implant procedures
- Increases patient satisfaction
- Reduces the need for repeat/repair surgeries
The MED is made of standard titanium alloy used in implant dentistry, and is shaped like a simple healing abutment, with a 1.25mm (0.05") hex socket.
Next steps:
0 Comments